We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M Turnover 25.81%
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-7.97%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$252M
AUM Growth
-$77.3M
Cap. Flow
+$25.4M
Cap. Flow %
10.07%
Top 10 Hldgs %
81.34%
Holding
31
New
5
Increased
9
Reduced
8
Closed
3
Avg Time Held Equity + Options
1.6 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1.6 years
Avg Time Held Equity only
1.7 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1.6 years

Top Buys

Rank Stock Value
1
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$62.6M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$7.41M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$5.15M
4
BPMC icon
Blueprint Medicines
BPMC
+$4.96M
5
SGMT icon
Sagimet Biosciences
SGMT
+$4.64M

Top Sells

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$46.9M
2
SLRN icon
ACELYRIN
SLRN
+$8.51M
3
IRON icon
Disc Medicine
IRON
+$5.01M
4
PLRX icon
Pliant Therapeutics
PLRX
+$1.78M
5
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$1.62M

Sector Composition

Rank Sector Weight
1 Healthcare 98.08%
2 Miscellaneous 1.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PLRX icon
1
Pliant Therapeutics
PLRX
$55.3M
$52.3M 20.72%
3,014,199
-102,818
-3% -$1.78M
2020 Q2
13 quarters
RPTX icon
2
DELISTED
Repare Therapeutics
RPTX
$35.8M 14.2%
2,966,674
-32,060
-1% -$331K
2020 Q2
13 quarters
CGEM icon
3
Cullinan Oncology
CGEM
$882M
$30.9M 12.25%
3,414,189
– –
2021 Q1
10 quarters
SLRN icon
4
DELISTED
ACELYRIN
SLRN
$23M 9.12%
2,262,990
-400,816
-15% -$8.51M
2023 Q2
1 quarter
ORTX
5
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$14M 5.56%
12,315,654
+11,559,916
+1,530% +$62.6M
2019 Q3
16 quarters
LRMR icon
6
Larimar Therapeutics
LRMR
$211M
$13.5M 5.35%
3,414,468
– –
2020 Q2
13 quarters
KROS icon
7
Keros Therapeutics
KROS
$219M
$13M 5.15%
407,633
+5,515
+1% +$206K
2020 Q2
13 quarters
IMA icon
8
ImageneBio Inc
IMA
$46M
$9.44M 3.74%
181,745
+4,908
+3% +$296K
2021 Q1
10 quarters
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$1.47B
$7.66M 3.04%
215,000
+130,000
+153% +$5.15M
2023 Q2
1 quarter
CMPX icon
10
Compass Therapeutics
CMPX
$152M
$5.57M 2.21%
2,829,712
– –
2021 Q4
7 quarters
MLYS icon
11
Mineralys Therapeutics
MLYS
$1.83B
$5.41M 2.14%
+568,379
New +$7.41M
2023 Q3
0 quarters
INZY icon
12
DELISTED
Inozyme Pharma
INZY
$5.33M 2.11%
1,270,027
+75,000
+6% +$382K
2020 Q3
12 quarters
SYRS icon
13
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.12M 2.03%
1,299,359
+531,914
+69% +$1.99M
2023 Q1
2 quarters
BPMC icon
14
DELISTED
Blueprint Medicines
BPMC
$4.66M 1.85%
+92,888
New +$4.96M
2023 Q3
0 quarters
LABD icon
15
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$59.1M
$4.64M 1.84%
22,500
-10,000
-31% -$1.62M
2023 Q2
1 quarter
TSVT icon
16
DELISTED
2seventy bio
TSVT
$3.93M 1.56%
1,002,007
+150,000
+18% +$984K
2022 Q1
6 quarters
MLTX icon
17
MoonLake Immunotherapeutics
MLTX
$831M
$3.42M 1.36%
+60,000
New +$3.31M
2023 Q3
0 quarters
OVID icon
18
Ovid Therapeutics
OVID
$428M
$3.32M 1.32%
864,822
– –
2019 Q3
16 quarters
SGMT icon
19
Sagimet Biosciences
SGMT
$612M
$3.07M 1.22%
+348,842
New +$4.64M
2023 Q3
0 quarters
OMGA icon
20
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$2.27M 0.9%
1,055,882
– –
2021 Q3
8 quarters
BDTX icon
21
Black Diamond Therapeutics
BDTX
$105M
$2.07M 0.82%
720,000
-30,000
-4% -$111K
2023 Q2
1 quarter
RLYB icon
22
Rallybio
RLYB
$87.3M
$1.32M 0.52%
48,842
-19,005
-28% -$823K
2022 Q3
4 quarters
IRON icon
23
Disc Medicine
IRON
$3.04B
$1.17M 0.47%
25,000
-100,139
-80% -$5.01M
2023 Q2
1 quarter
LENZ icon
24
LENZ Therapeutics
LENZ
$102M
$573K 0.23%
32,991
– –
2023 Q2
1 quarter
FRLN
25
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$373K 0.15%
86,654
+64,988
+300% +$257K
2020 Q3
12 quarters
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, CHI Advisors held 31 positions worth $252M, down 23% from $330M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

CHI Advisors deployed $25.4M of net new capital in Q3 2023, opening 5 new positions and adding to 9 existing holdings. Its largest new stake was Mineralys Therapeutics: 568,379 shares worth $5.41M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was ACELYRIN, an estimated $8.51M trimmed.

  • CHI Advisors's largest Q3 2023 buy was Mineralys Therapeutics: 568,379 shares worth $5.41M.
  • CHI Advisors added most to Orchard Therapeutics plc American Depositary Shares in Q3 2023, an estimated $62.6M increase.
  • CHI Advisors's biggest Q3 2023 reduction was ACELYRIN, cutting an estimated $8.51M.
  • CHI Advisors fully exited VectivBio Holding AG Ordinary Shares in Q3 2023, selling an estimated $46.9M.
  • CHI Advisors's ten largest holdings make up 81% of its $252M portfolio in Q3 2023.
  • CHI Advisors opened 5 new positions and closed 3 in Q3 2023.
  • CHI Advisors's portfolio value fell 23% quarter-over-quarter to $252M.

Based on CHI Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.